The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Eli Lilly has announced a daily pill that lowers blood sugar levels and promotes weight loss in individuals suffering from ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral ...

Eli Lilly's new diabetes pill, orforglipron, matches the performance of Ozempic in reducing weight and blood sugar. With promising clinical trial results and plans for regulatory approval, Lilly is ...

Employers face rising GLP-1 demand. Here are tips to manage costs while maintaining care access.

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...